Transradial Aortic Valvuloplasty: Is Minimalism Worth It?

Balloon aortic valvuloplasty (BAV) has historically been used either as a bridge strategy, an assessment tool, or even palliative treatment in severe aortic stenosis (AS) patients, particularly unstable ones or with valve replacement contraindications. Although the femoral approach has traditionally been the main access route, it remains associated to a non-negligible complications rate — mainly vascular — comparable to rates seen in TAVR. In this context, the transradial approach, widely mastered by interventional cardiology teams, emerges as an appealing alternative.

The study presented at JSCAI and conducted at the Henry Ford Health System conducted a comparative analysis between transradial (TRV) and transfemoral (TFV) BAV, assessing technical and hemodynamic success, periprocedural safety, and short-term clinical outcomes.

A total of 253 consecutive patients were included between 2021 and 2024. Propensity-score adjustment and multivariable modeling were used to minimize bias.

TRV was feasible in most cases (96.2%), achieving a hemodynamic success rate similar to TFV (78.1% vs. 75%; p = NS). Notably, in this cohort, the transradial approach was associated with a significant reduction in the composite primary endpoint (VARC-3) — major vascular complications, grade 3–4 bleeding, balloon embolization, periprocedural death, and non-access-related events — with 2.5% vs. 17.5% incidence rates (adjusted OR 0.13; 95% CI: 0.04–0.49; p = 0.003).

Events related to vascular access were ten times lower with TRV (0.9% vs. 9.4%; p=0.041), with a single case of balloon entrapment noted, which was resolved without vascular injury. Non–access-related events were also lower (1.6% vs. 7.2%; adjOR 0.20; p=0.034). In addition, both procedure time and contrast volume were significantly reduced in the radial group, with an average decrease of 34 minutes and 34 mL, respectively.

Read also: Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure: Cohort Study with Continuous Implantable Cardiac Monitoring.

There were no differences in periprocedural mortality or in secondary 30-day outcomes (mortality, rehospitalization, discharge failure), which were similar between groups. It is worth noting that transradial patient selection was guided by ultrasound and anatomical criteria (>2.5 mm diameter and no circumferential calcification), excluding patients with AV fistulas or end-stage kidney disease. There was a low conversion rate to the femoral approach (3.8%).

Conclusions

This study supports the feasibility and safety of transradial BAV, with comparable technical and hemodynamic success rates but clearly superior safety profile. The relevance of these findings is particularly significant in frail patients or those at high vascular risk.

Original Title: Comparative Effectiveness of Balloon Aortic Valvuloplasty via Transradial and Transfemoral Access

Reference: Fang JX, Villablanca PA, Frisoli TM, Engel Gonzalez P, Lee JC, Fram GK, et al. Comparative Effectiveness of Balloon Aortic Valvuloplasty via Transradial and Transfemoral Access. Journal of the Society for Cardiovascular Angiography & Interventions [Internet]. [cited 2025 Nov 18]; Available from: https://doi.org/10.1016/j.jscai.2025.104015.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHAMPION-AF: Left atrial appendage closure versus anticoagulation in atrial fibrillation

Can left atrial appendage closure challenge anticoagulation as the standard of care in atrial fibrillation? Atrial fibrillation (AF) is the most common sustained arrhythmia and...

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...